shanghai zhangjiang biomedical industry venture capital
MicuRx Raises US$25m For US-China Antibiotic Clinical Trial
MicuRx Pharma has raised US$25 million in Series B financing to carry out clinical trials on its MRX-I antibiotic candidate.
Shanghai MengKe Pharma To Develop MRX-I Antibiotic For Chinese Market
MicuRx Pharma and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced a joint venture to develop MRX-I for the Chinese market.